ROIV insider trading
NasdaqGS HealthcareRoivant Sciences Ltd.: insider trade history from SEC Form 4 filings.
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Company website: roivant.com
ROIV insider activity at a glance
FilingIQ tracks 808 insider transactions for ROIV in filings since Mar 9, 2022. The most recent transaction is dated Oct 1, 2026.
Across the full history, 4 open-market purchases
and 295 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ROIV insider trades is 61.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ROIV Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ROIV
13F funds holding ROIV
Frequently asked
- How many insider trades does FilingIQ track for ROIV?
- FilingIQ tracks 808 Form 4 insider transactions for ROIV (Roivant Sciences Ltd.), covering filings from Mar 9, 2022 onwards. 51 of those are dated within the last 90 days.
- Are ROIV insiders net buyers or net sellers?
- Across the full Form 4 history for ROIV, 4 transactions (0%) were open-market purchases and 295 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ROIV insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ROIV in?
- Roivant Sciences Ltd. (ROIV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $19.87B.
Methodology & sources
Every ROIV insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.